Pharmaceutical Business review

Bioheart acquires distribution rights to RTX’s heart failure monitor

The Bioheart 3370 heart failure monitor collects data from a range of vital sign monitoring devices, a weight scale and a voice-activated heart failure status questionnaire, and provides for secure data transmission to an HTTP server on the Internet.

The monitor is designed with unique features that make the device state-of-the-art for system integrators working the area of home monitoring, e-health and remote disease management. Regular data input and monitoring enables the health care team to detect signs and symptoms of change as they occur.

The device, manufactured by RTX Healthcare, has 510k market clearance from the FDA for marketing in the US and CE mark approval for marketing in Europe and other countries that follow this mark.

The company is planning to begin immediate commercial distribution. The Bioheart 3370 at-home heart failure monitor will be available through physician prescription.